Lefitolimod is under clinical development by Mologen and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Lefitolimod’s likelihood of approval (LoA) and phase transition for Solid Tumor took place on 27 Jun 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Lefitolimod Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
MGN-1703 (lefitolimod) is under development for the treatment of solid tumors, small cell lung cancer and chronic HIV-1 Infection. The drug candidate is administered subcutaneously as a solution. It acts by targeting Toll-like receptors 9 (TLR9). The drug candidate is based on dSLIM (double stem-loop immunomodulator) technology platform.
The drug candidate was under development for the treatment of metastatic colorectal carcer.
Mologen is a biotechnology engaged in the development of novel drugs, immunotherapies and active ingredients. The company develops various pipeline products which include MGN1601, and others. It also engaged in developing EnanDIM product to treat antitumor efficacy by stimulating TLR9 receptor on certain cells of the immune system. The company’s pipeline product Lefitolimod acts like a toll receptor which helps in activating the immune system. It also develops tolerable drugs in fields of oncology and on other serious infectious diseases. Mologen is headquartered in Berlin, Germany.
Quick View Lefitolimod LOA Data
|Highest Development Stage|